Cordlife GroupCLIFF 33 Days Inventory is 22.71 as of Mar. 2026, which is 7% above its 10-year median of 21.23. GuruFocus rates CLIFF with a GF Score™ of 33/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 176 Medical Diagnostics & Research companies, Cordlife Group ranks better than 83.52% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Cordlife Group's Average Total Inventories for the
three
months ended in Mar. 2026 was $0.74 Mil. Cordlife Group's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.96 Mil.
Hence, Cordlife Group's Days Inventory for the
three
months ended in Mar. 2026 was 22.71.
The historical rank and industry rank for Cordlife Group's Days Inventory or its related term are showing as below:
CLIFF'
s Days Inventory Range Over the Past 10 Years
Min: 15.55 Med: 21.23 Max: 32.78
Current: 22
During the past 13 years, Cordlife Group's highest Days Inventory was 32.78. The lowest was 15.55. And the median was 21.23.
CLIFF's Days Inventory is ranked better than 83.52% of 176
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.88
vs CLIFF: 22.00
Cordlife Group's Days Inventory
increased
from Mar. 2025 (19.76) to Mar. 2026 (22.71).
It might indicate that Cordlife Group's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Cordlife Group's Inventory Turnover for the
three
months ended in Mar. 2026 was 4.02.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cordlife Group's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.10.
Cordlife Group (OTCPK:CLIFF) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Cordlife Group's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Cordlife Group's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Cordlife Group Days Inventory Related Terms
Cordlife Group Days Inventory Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Days Inventory distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cordlife Group (CLIFF) has a Days Inventory of 22.71 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cordlife Group and its competitors. This is near median its historical median of 21.23. Over the past decade, Cordlife Group's Days Inventory has ranged from 15.55 to 32.78. According to the industry distribution chart, Cordlife Group ranks #29 out of 176 companies in the Medical Diagnostics & Research industry, placing it in the top 16.5%.
Is Cordlife Group's Days Inventory too high?
Cordlife Group's current Days Inventory of 22.71 is near median its 10-year median of 21.23. Over the past 10 years, this metric has ranged from a low of 15.55 to a high of 32.78. The Medical Diagnostics & Research industry median Days Inventory is 68.88. Cordlife Group's value of 22.71 is 67% below this industry median. Based on the distribution chart, Cordlife Group ranks #29 out of 176 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #29 out of 176 companies for Days Inventory. This places Cordlife Group in the top 17% of its industry — outperforming the majority of peers. The industry median Days Inventory is 68.88. Cordlife Group's value of 22.71 is 67% below this benchmark. Historically, Cordlife Group's own Days Inventory has ranged from 15.55 to 32.78 over the past decade. While the company's 10-year median is 21.23 vs. the industry median of 68.88, Cordlife Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 68.88, based on 176 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cordlife Group's current Days Inventory of 22.71 is 67% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Cordlife Group and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 68.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cordlife Group's current Days Inventory is 22.71, which is near median its own 10-year median of 21.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $0.15 — trading 24.8% below its estimated fair value. The current Days Inventory is 22.71, which is near median its 10-year median of 21.23 and 67% below the Medical Diagnostics & Research industry median of 68.88. Cordlife Group's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Days Inventory is 22.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 24.8% below its estimated GF Value™ of $0.20.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
Days Inventory: 22.71 (near median its 10-year median of 21.23)
GF Value™: $0.20 vs. price of $0.15 (24.8% below fair value)
Industry Position: 67% below the Medical Diagnostics & Research median (#29 of 176)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
33GF Score
Get the complete analysis for CLIFF
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
